RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells
Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...
Prif Awduron: | Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li |
---|---|
Fformat: | Erthygl |
Iaith: | English |
Cyhoeddwyd: |
Elsevier
2024-02-01
|
Cyfres: | Neoplasia: An International Journal for Oncology Research |
Pynciau: | |
Mynediad Ar-lein: | http://www.sciencedirect.com/science/article/pii/S1476558624000046 |
Eitemau Tebyg
-
RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
gan: Wentao Si, et al.
Cyhoeddwyd: (2022-11-01) -
RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
gan: Natalia B. Fernández, et al.
Cyhoeddwyd: (2023-01-01) -
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
gan: Bradley A. Hancock, et al.
Cyhoeddwyd: (2019-08-01) -
Comprehensive Analysis of RUNX and TGF-β Mediated Regulation of Immune Cell Infiltration in Breast Cancer
gan: Liang Gao, et al.
Cyhoeddwyd: (2021-08-01) -
TGF-β induced reprogramming and drug resistance in triple-negative breast cells
gan: Guoyu Wu, et al.
Cyhoeddwyd: (2022-04-01)